Compugen Q2 EPS $(0.02) Beats $(0.07) Estimate, Sales $6.70M
Portfolio Pulse from Benzinga Newsdesk
Compugen (NASDAQ:CGEN) reported Q2 EPS of $(0.02), beating the $(0.07) estimate by 71.43%. Sales were $6.70M, surpassing the $2.49M estimate by 169.16%.
August 06, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compugen reported Q2 EPS of $(0.02), significantly beating the $(0.07) estimate. Sales were $6.70M, far exceeding the $2.49M estimate. This strong performance is likely to positively impact the stock price in the short term.
The significant beat on both EPS and sales estimates indicates strong financial performance, which is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100